G1 THERAPEUTICS’s (NASDAQ:GTHX) lock-up period is set to end on Monday, November 13th. G1 THERAPEUTICS had issued 7,000,000 shares in its IPO on May 17th. The total size of the offering was $105,000,000 based on an initial share price of $15.00. After the end of the company’s lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

GTHX has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Cowen and Company reissued a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $29.75.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/11/07/g1-therapeuticss-gthx-lock-up-period-to-end-on-november-13th.html.

Shares of G1 THERAPEUTICS (GTHX) opened at $23.10 on Wednesday. G1 THERAPEUTICS has a one year low of $12.04 and a one year high of $28.67.

G1 THERAPEUTICS (NASDAQ:GTHX) last issued its earnings results on Wednesday, August 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.48). analysts expect that G1 THERAPEUTICS will post -2.7 earnings per share for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Alps Advisors Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $444,000. Bank of New York Mellon Corp purchased a new stake in shares of G1 THERAPEUTICS during the third quarter valued at $568,000. Victory Capital Management Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $889,000. Goldman Sachs Group Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $1,144,000. Finally, Vanguard Group Inc. purchased a new stake in shares of G1 THERAPEUTICS during the second quarter valued at $1,291,000. 35.18% of the stock is owned by hedge funds and other institutional investors.

G1 THERAPEUTICS Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.